Involvement of JNK pathway in the promotion of the early stage of colorectal carcinogenesis under high-fat dietary conditions

Gut

Volumn 58, Issue 12, 2009, Pages 1637-1643

  Endo, H ^a   Hosono, K ^a   Fujisawa, T ^a   Takahashi, H ^a   Sugiyama, M ^a   Yoneda, K ^a   Nozaki, Y ^a   Fujita, K ^a   Yoneda, M ^a   Inamori, M ^a   Wada, K ^b   Nakagama, H ^c   Nakajima, A ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; AZOXYMETHANE; CHOLESTEROL; GLUCOSE; INSULIN; STRESS ACTIVATED PROTEIN KINASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTESTINE CRYPT; LIPID DIET; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

ANIMALS; AZOXYMETHANE; CARCINOGENS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLON; COLORECTAL NEOPLASMS; DIETARY FATS; DISEASE MODELS, ANIMAL; HUMANS; INSULIN; INSULIN RESISTANCE; INTESTINAL MUCOSA; MAP KINASE KINASE 4; MICE; MICE, INBRED C57BL; SIGNAL TRANSDUCTION;

EID: 72549119225     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.183624     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Giovannucci E, Goldin B. The role of fat, fatty acids, and total energy intake in the etiology of human colon cancer. Am J Clin Nutr 1997;66:1564S-71S.
3. Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr 2002;132:3456S-64S.
4. Giovannucci E, Willett WC. Dietary factors and risk of colon cancer. Ann Med 1994;26:443-452
5. Lasko CM, Bird RP. Modulation of aberrant crypt foci by dietary fat and caloric restriction: the effects of delayed intervention. Cancer Epidemiol Biomarkers Prev 1995;4:49-55.
6. Rao CV, Hirose Y, Indranie C, et al. Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids. Cancer Res 2001;61:1927-1933 (Pubitemid 32692009)
7. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001;131:3109S-20S.
8. Corpet DE, Jacquinet C, Peiffer G, et al. Insulin injections promote the growth of aberrant crypt foci in the colon of rats. Nutr Cancer 1997;27:316-320 (Pubitemid 27161531)
9. Tran TT, Medline A, Bruce WR. Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomarkers Prev 1996;5:1013-1015 (Pubitemid 26415875)
10. Tran TT, Naigamwalla D, Oprescu AI, et al. Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in vivo. Endocrinology 2006;147:1830-1837
11. Aparicio T, Kotelevets L, Tsocas A, et al. Leptin stimulates the proliferation of human colon cancer cells in vitro but does not promote the growth of colon cancer xenografts in nude mice or intestinal tumorigenesis in Apc(Min/+) mice. Gut 2005;54:1136-1145 (Pubitemid 41025909)
12. Fujisawa T, Endo H, Tomimoto A, et al. Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut 2008;57:1531-1538
13. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333-336 (Pubitemid 35398190)
14. Solinas G, Naugler W, Galimi F, et al. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc Natl Acad Sci USA 2006;103:16454-16459 (Pubitemid 44715217)
15. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-252
16. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997;9:240-246
17. Yang YM, Bost F, Charbono W, et al. C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin Cancer Res 2003;9:391-401.
18. Gross ND, Boyle JO, Du B, et al. Inhibition of Jun NH2-terminal kinases suppresses the growth of experimental head and neck squamous cell carcinoma. Clin Cancer Res 2007;13:5910-5917 (Pubitemid 47583919)
19. Hideshima T, Hayashi T, Chauhan D, et al. Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines. Oncogene 2003;22:8797-8801
20. Mingo-Sion AM, Marietta PM, Koller E, et al. Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells. Oncogene 2004;23:596-604. (Pubitemid 38175015)
21. Nateri AS, Spencer-Dene B, Behrens A. Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development. Nature 2005;437:281-285 (Pubitemid 41294493)
22. Hardwick JC, van den Brink GR, Offerhaus GJ, et al. NF-kappaB, p38 MAPK and JNK are highly expressed and active in the stroma of human colonic adenomatous polyps. Oncogene 2001;20:819-827
23. Wang H, Birkenbach M, Hart J. Expression of Jun family members in human colorectal adenocarcinoma. Carcinogenesis 2000;21:1313-1317 (Pubitemid 30455989)
24. Osawa E, Nakajima A, Wada K, et al. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003;124:361-367 (Pubitemid 36169253)
25. Boussiotis VA, Freeman GJ, Taylor PA, et al. p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat Med 2000;6:290-297
26. McLellan EA, Bird RP. Aberrant crypts: potential preneoplastic lesions in the murine colon. Cancer Res 1988;48:6187-6192
27. Konstantakos AK, Siu IM, Pretlow TG, et al. Human aberrant crypt foci with carcinoma in situ from a patient with sporadic colon cancer. Gastroenterology 1996;111:772-777
28. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001;98:10983-10985 (Pubitemid 32928669)
29. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-2927
30. Zick Y. Insulin resistance: a phosphorylation-based uncoupling of insulin signaling. Trends Cell Biol 2001;11:437-441 (Pubitemid 33001425)
31. Aguirre V, Werner ED, Giraud J, et al. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 2002;277:1531-1537 (Pubitemid 34968910)
32. De Fea K, Roth RA. Modulation of insulin receptor substrate-1 tyrosine phosphorylation and function by mitogen-activated protein kinase. J Biol Chem 1997;272:31400-31406 (Pubitemid 28013276)
33. Ozes ON, Akca H, Mayo LD, et al. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc Natl Acad Sci USA 2001;98:4640-4645 (Pubitemid 32295029)
34. Um SH, D'Alessio D, Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab 2006;3:393-402. (Pubitemid 43811780)
35. Park HS, Kim MS, Huh SH, et al. Akt (protein kinase B) negatively regulates SEK1 by means of protein phosphorylation. J Biol Chem 2002;277:2573-2578 (Pubitemid 34953281)
36. Brazil DP, Park J, Hemmings BA. PKB binding proteins. Getting in on the Akt. Cell 2002;111:293-303.
37. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001;20:2390-2400
38. Kiunga GA, Raju J, Sabljic N, et al. Elevated insulin receptor protein expression in experimentally induced colonic tumors. Cancer Lett 2004;211:145-153 (Pubitemid 38824628)
39. Kaneto H, Nakatani Y, Miyatsuka T, et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med 2004;10:1128-1132 (Pubitemid 39424876)
40. Avruch J, Belham C, Weng Q, et al. The p70 S6 kinase integrates nutrient and growth signals to control translational capacity. Prog Mol Subcell Biol 2001;26:115-154
41. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
42. Um SH, Frigerio F, Watanabe M, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004;431:200-205 (Pubitemid 39243474)
43. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40. (Pubitemid 32225829)
44. Wang W, Zhou G, Hu MC, et al. Activation of the hematopoietic progenitor kinase-1 (HPK1)-dependent, stress-activated c-Jun N-terminal kinase (JNK) pathway by transforming growth factor beta (TGF-beta)-activated kinase (TAK1), a kinase mediator of TGF beta signal transduction. J Biol Chem 1997;272:22771-22775 (Pubitemid 27386096)
45. Roberts AB, Anzano MA, Wakefield LM, et al. Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci USA 1985;82:119-123 (Pubitemid 15168226)
46. Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002;12:22-29 (Pubitemid 34094985)
47. Raju J, McCarthy B, Bird RP. Steady state levels of transforming growth factor-beta1 and -beta2 mRNA and protein expression are elevated in colonic tumors in vivo irrespective of dietary lipids intervention. Int J Cancer 2002;100:635-641 (Pubitemid 34832972)
48. Endo H, Fujisawa T, Takahashi H, et al. Author response to GUT/2009/177535. Gut 2009;58:1169-1170